Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 4 Results

Intervention Indication Therapeutic Area Year Actions
Apalutamide in Addition to Abiraterone and Prednisone/Prednisolone for Metastatic Castration-resistant Prostate Cancer – First Line Abiraterone acetate (Zytiga; Yonsa) , Apalutamide (Erleada; ARN-509) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2018 View  |  Download
Daratumumab in combination with Bortezomib, Melphalan and Prednisone for Multiple Myeloma – first line Bortezomib (Velcade; bortezomib mannitol boronic ester) , Daratumumab (Darzalex; JNJ-54767414) , Melphalan , Prednisone (Decadron; Lodotra) Multiple myeloma (MM) Haematological Cancer and Lymphomas 2018 View  |  Download
Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line Abiraterone acetate (Zytiga; Yonsa) , Ipatasertib (GDC-0068; RG7440) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2020 View  |  Download
Niraparib with abiraterone acetate and prednisone for metastatic castration resistant prostate cancer Abiraterone acetate (Zytiga; Yonsa) , Niraparib (Zejula; MK 4827; JNJ 64091742; GSK 3985771; niraparib tosylate monohydrate) , Prednisone (Decadron; Lodotra) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications